LFA-1-dependent tumoricidal activity of cisplatin-treated macrophages

Immunology and Cell Biology

Volumn 76, Issue 4, 1998, Pages 343-349

  Singh, Rana A K ^a   Sodhi, Ajit ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Ca2+; Calmodulin; Cisplatin; Cytotoxicity; Kinases; LFA 1; Macrophages; Phosphatases

Indexed keywords

CALCINEURIN; CISPLATIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE C; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CYTOTOXICITY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM; CALMODULIN; CISPLATIN; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; INTERLEUKIN-1; L CELLS (CELL LINE); LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0031857942     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00751.x     Document Type: Article

References (36)

1. Adams DO, Hamilton TA. Molecular transductional mechanisms by which IFN-Y and other signals regulate macrophage development. Immunol. Rev. 1987; 127: 25-50.
2. Fidler IJ, Schroitt AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochem. Biophys. Acta 1988; 948: 151-73.
3. Fidler IJ. Macrophage and metastasis: A biological approach to cancer therapy: Presidential address. Cancer Res. 1985; 45: 4717-26.
4. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55: 2303-16.
5. Sodhi A, Singh SM. Release of cytolytic factor(s) by murine macrophages in vitro on treatment with cisplatin. Int. J. Immunopharmacol. 1986; 8: 701-7.
6. Sodhi A, Kumar R. Production of nitric oxide and its regulation in murine peritoneal macrophages treated with cisplatin and lipopolysaccharide. Int. J. Immupathol. Immunopharmacol. 1994; 7: 65-77.
7. Gupta P, Sodhi A. Effect of cisplatin on release of lysozyme, plasminogen activator, leucine aminopeptidase and beta-hexosaminidase by murine peritoneal macrophages in vitro. Ind. J. Exp. Biol. 1988; 26: 679-84.
8. Sodhi A, Gupta P. Increased release of hydrogen peroxide and superoxide anion by murine macrophages in vitro after cisplatin treatment. Int. J. Immunopharmacol. 1986; 8: 709-14.
9. Sodhi A, Shishodia S, Shrivastava S. Cisplatin-stimulated murine hone marrow-derived macrophages secrete oncostatin M. Imm. Cell Biol. 1997; 75: 492-6.
10. Meltzer MS. Tumor cytotoxicity by lymphokine-activated macrophages: Development of macrophage tumoricidal activity requires a sequence of reactions. In: Pick E (ed.) Lymphokines. New York: Academic Press, 1981; 3: 319-29.
11. Mantovani A. Cytotoxic killing of tumor cells by monocytes. In: Zembala M, Asherson GL (eds) Human monocytes. London: Academic Press, 1989; 303-11.
12. Piessens WF. Increased binding of tumor cells by macrophages activated in vitro with lymphocyte mediators. Cell Immunol. 1979; 35: 303-17.
13. Singh SM, Sodhi A. Interaction between cisplatin treated macrophages and Dalton's lymphoma cells in vitro. Exp. Cell Res. 1988; 56: 1-11.
14. Ptarroyom M, Makgoba MW. Leukocyte adhesion to cell: Molecular basis, physiological relevance, and abnormalities. Scand. J. Immunol. 1989; 30: 129-64.
15. Fawcett J, Holness CLL, Needham LA, Turley H, Gatler KC, Simmons DY. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992; 360: 481-6.
16. Kumar R, Sodhi S. Activation of murine peritoneal macrophages with cisplatin and lipopolysaccharide: Involvement of protein kinase C and tyrosine kinase. J. Clin. Biochem. Nutr. 1994; 17: 55-64.
17. Sodhi A, Kumar R. Role of calcium and calmodulin in the activation of murine peritoneal macrophages with cisplatin. Int. J. Immunopharmacol. 1994; 16: 1003-10.
18. Ding AH, Nathan CF, Stuethr, DJ. Release of reactive nitrogen intermediate and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production J. Immunol. 1988; 141: 2407-12.
19. Mathews N, Neale ML. Cytotoxicity assays for tumor necrosis factor and lymphotoxin. In: Clemens MJ, Morris AG and Gearing AJH (eds) Lymphokines and Interferons. Oxford: IRL Press, 1987; 221-6.
20. Mizel SB. IL-1 and T cell activation. Immunol. Rev. 1982; 63: 51-72.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 1976; 72: 248-54.
22. Vierira A, Robert GE, Kuchler K. Western blotting and ligand blotting using enhanced chemiluminescence and radioiodine detection. In: Cell Biology: A Laboratory Handbook. San Diego USA: Academic Press 1994; 2: 314-21.
23. Peri G, Chiaffarino F, Bernasconi S, Martin Padura I, Mantovani A. Cytotoxicity of activated monocytes on endothelial cells. J. Immunol. 1990; 144: 1444-8.
24. Hardie DG, Haystead TAJ, Sim ATR. Use of okadaic acid to inhibit protein phosphatases in intact cells. Method. Enzymol. 1991; 201: 469-76.
25. Fuziki H, Suganuma M. Tumor promotion by inhibitors of protein phosphatases 1 and 2A. Adv. Cancer Res. 1993; 61: 143-94.
26. Gordon JA. Use of vanadate as protein phosphotyrosine phosphatases inhibitor. Method. Enzymol. 1991; 201: 477-82.
27. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinoline sulphonamides, novel potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984; 23: 5036-41.
28. Akiyama T, Ishida J, Nakagawa S et al. Genestein: A specific inhibitor of tyrosine specific kinases. J. Biol. Chem. 1987; 262: 5592-5.
29. 2+ requirement for initiation of lymphocyte growth. Biochem. Soc. Trans. 1980; 8: 721-6.
30. 2+ antagonist, 8-(N, N-dimethlyamino)octyl-3,4,5-trimethoxybenzoate hydrochloride in smooth and skeletal muscles. Brit. J. Pharmacol. 1975; 53: 279-83.
31. Hiserodt JC, Britvan LJ, Targan SR. Differential effects of various pharmacological agents on the cytologic reaction mechanism of the human natural killer lymphocytes: Further resolution of programming for lysis and KC1L into discrete states. J. Immunol. 1982; 129: 2266-70.
32. Hidaka A, Kobayashi R. Use of protein (serine threonine) kinase activators and inhibitors to study protein phosphorylation in intact cells. In: Hardie DG (ed.) Protein Phosphorylation: A Practical Approach. Oxford: IRL Press, 1993; 87-107.
33. Strassmann G, Springer TA, Somers SD, Adams DO. Mechanism of tumor cell capture by activated macrophages: Evidence for involvement of lymphocyte function associated (LFA-1) antigen. J. Immunol. 1986; 136: 4328-33.
34. Bernasconi S, Peri G, Sironi M, Mantovani A. Involvement of leukocyte (β2) integrins (CD18/CD11) in human monocyte tumoricidal activity. Int. J. Cancer 1991; 49: 267-73.
35. Kurzinger K, Reynolds T, Germain RN, Davignon D, Martz E, Springer TA. A novel lymphocyte function-associated antigen (LFA-1) cellular distribution and, quantitative expression, and structure. J. Immunol. 1981; 127: 596-600.
36. Strassmann G, Springer TA, Adams DO. Studies on antigens associated with the activation of murine mononuclear phagocytes: Kinetics of and requirements for induction of Lymphocyte Function-Associated (LFA)-1 Antigen in vitro. J. Immunol. 1985; 135: 147-51.